| Recruiting | 1 | 250 | Europe, US, RoW | ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets | ORIC Pharmaceuticals | Metastatic Prostate Cancer | 12/24 | 09/26 | | |